Q-omics provides the consensus-scored DCAKD profile across patient tissues and cancer cell-line models. DCAKD expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, DCAKD is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, DCAKD RNA expression shows 20,397 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCEC, KICH, and LSCC as cancer lineages where DCAKD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCAKD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCAKD survival associations across molecular data types. DCAKD RNA expression shows survival associations in the most cancer types (28), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCAKD RNA expression–survival associations across cancer types. High DCAKD expression shows unfavorable associations in KIRC and SKCM, but favorable associations in UCEC, BRCA, HNSC and LUSC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for DCAKD RNA expression.
This table summarizes DCAKD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DCAKD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCAKD shows lower tumor expression in KICH, KIRC and BRCA and higher tumor expression in LUSC, LIHC and COAD. The KICH box plot shows higher DCAKD RNA expression in normal versus tumor tissue (log2 FC = −1.048, t-test p < 0.001).
This table shows molecular features associated with DCAKD in patient tissues and cancer cell lines. In patient samples, DCAKD shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DCAKD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
